Download APSHO's free guide, 'Conference Hacks: Maximizing Your Exhibit Hall Experience,' for expert tips on navigating exhibit halls, networking, and staying updated on the latest technologies. Click below to get yours!
| Second-Line CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) |
|
In this Educator Module, F. Brianne Buchanan, PA-C, of The University of North Carolina at Chapel Hill, provides a comprehensive overview of the evolving treatment landscape of second-line CAR-T cell therapy for patients with diffuse large B-cell lymphoma. Ms. Buchanan discusses associated challenges and considerations, including patient selection, contraindications, treatment-related toxicity, and logistical issues for patients, as well as future directions for CAR T-cell therapy in this patient population. Funding and support provided by Bristol Myers Squibb and Kite, a Gilead Company
Take a short survey and earn your certificate of participation!
APSHO members: Login here APSHO non-members: Create an APSHO guest non-member profile first by clicking here. Once you’ve created your APSHO profile, follow the prompts to the survey and the certificate. Meet The Faculty
Lead Author
F. Brianne Buchanan, PA-C
University of North Carolina at Chapel Hill Brianne Buchanan is a physician assistant working for the Bone Marrow Transplant and Cellular Therapy Program at the University of North Carolina (UNC) Chapel Hill since 2013. Her clinical focus is working with patients receiving both commercial
and research CAR-T therapies and on CAR-T program development, which she has been extensively involved with since 2016. Prior to working at UNC, she worked in both bone marrow transplant and outreach oncology at Duke University. Ms. Buchanan
received her PA degree from George Washington University in 2005.
Reviewer
Danielle Bull, MSN, CRNP, FNP-BC AGACNP-BC
Fox Chase Cancer Center Danielle Bull is a dual-certified acute and family nurse practitioner specializing in hematology, oncology, and cellular therapy at Fox Chase Cancer Center. With a strong focus on cellular and CAR-T therapies, she has extensive experience
in managing complex patient populations and advancing clinical care. Ms. Bull is recognized for designing innovative programs, leading clinical trials, and providing educational support to healthcare providers. As the lead advanced practice
provider at Fox Chase, she plays a pivotal role in patient care, while also contributing to clinical data abstraction at Flatiron Health. Ms. Bull holds advanced degrees from the University of Pennsylvania and Thomas Jefferson University,
along with multiple certifications.
Reviewer
Kendra Yum, PharmD, BCOP
Mount Sinai Hospital Kendra Yum is an oncology clinical manager at Mount Sinai Hospital in New York, where she has practiced in the Investigational Drug Service as well as the Blood and Marrow Transplant and Cellular Therapy Service for 12 years. Dr. Yum serves
as the secretary of the Hematology/Oncology Pharmacy & Therapeutics subcommittee in the Mount Sinai Health System. She is also the program director of the Oncology Pharmacy Residency Program (PGY2) and precepts students and residents
from other programs. Dr. Yum earned her PharmD from University of Michigan College of Pharmacy and completed her pharmacy residency training at Thomas Jefferson University Hospital (PGY1) and Mount Sinai Hospital (PGY2). Her research interests
include complications related to blood and marrow transplant.
|